Frank Knudsen
Nessuna posizione attualmente
Storia della carriera di Frank Knudsen
Precedenti posizioni note di Frank Knudsen
Società | Posizione | Inizio | Fine |
---|---|---|---|
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Direttore/Membro del Consiglio | 01/01/2015 | 07/10/2020 |
Presidente | 01/01/2015 | 01/01/2018 | |
Independent Dir/Board Member | - | 07/10/2020 | |
SEED Capital Management I/S
SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark. | Investitore di Private Equity | 01/01/2006 | 31/05/2014 |
MycoTeQ A/S
MycoTeQ A/S Pharmaceuticals: MajorHealth Technology MycoTeQ is working to ease the discovery process for the pharmaceutical industry in order to ensure a steady flow of new chemical entities into the pipelines of this industry. The aspiration of MycoTeQ is to build a healthy business and become the world leading external provider of new chemical entities from micro fungi. In order to succeed on these ambitious targets MycoTeQ will adhere to the highest professional and scientific standards and seek to build strong and long-lasting relationships with its partners and customers. The company was founded in October 2006 and is headquartered in Copenhagen, Denmark. | Direttore/Membro del Consiglio | - | 02/04/2012 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Direttore/Membro del Consiglio | 07/07/2009 | 30/07/2010 |
Teknologisk Institut
Teknologisk Institut Miscellaneous Commercial ServicesCommercial Services Teknologisk Institut develops, applies, and disseminates research- and technology-based knowledge for the Danish business. It is an independent, non-profit institution that provides training courses and conferences including information technology courses; energy and construction; project; personal development; leadership; productivity, measuring technology, and logistics; quality; food and environment; communication; sales and marketing; and human resource, law, and economics. In addition, it also carries out consultancy and standardization activities. The firm provides services in business areas such as building and construction; business and industrial development; chemistry and biotechnology; energy and climate; environment, working environment, and health; food and packaging; industrial measurements and control; industrial production and development; meat industry solutions; productivity and management; surfaces and microtechnology; and transport and logistics. The company was founded by Gunnar Gregersen in 1906 and is headquartered in Taastrup, Denmark. | Corporate Officer/Principal | 01/01/1996 | 01/01/2001 |
The European Commission | Corporate Officer/Principal | 01/01/1989 | 01/01/1996 |
Diet4life ApS
Diet4life ApS BiotechnologyHealth Technology Diet4life ApS produces dietary supplements to reduce fat accumulation and induce weight loss in the human body. It evaluate the long-term effects of regular protein intake in conjunction with certain food products and the suitability for being a dietary supplement. The company was founded on March 4, 2013 and is headquartered in Aarhus, Denmark. | Direttore/Membro del Consiglio | - | - |
Valderm ApS
Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Direttore/Membro del Consiglio | - | - |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Direttore/Membro del Consiglio | - | - |
░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░░░░░░░░ ░░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░░ ░░░ | ░░░░░░░░ | - | - |
░░░░░░░ ░░ ░░ ░░░ ░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░ ░░ ░ ░░░ ░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Statistiche
Distribuzione geografica
Danimarca | 21 |
Belgio | 2 |
Posizioni
Director/Board Member | 15 |
Chairman | 3 |
Corporate Officer/Principal | 2 |
Settori
Health Technology | 15 |
Government | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
CURASIGHT A/S | Health Technology |
Aziende private | 20 |
---|---|
Glycom A/S
Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Health Technology |
MycoTeQ A/S
MycoTeQ A/S Pharmaceuticals: MajorHealth Technology MycoTeQ is working to ease the discovery process for the pharmaceutical industry in order to ensure a steady flow of new chemical entities into the pipelines of this industry. The aspiration of MycoTeQ is to build a healthy business and become the world leading external provider of new chemical entities from micro fungi. In order to succeed on these ambitious targets MycoTeQ will adhere to the highest professional and scientific standards and seek to build strong and long-lasting relationships with its partners and customers. The company was founded in October 2006 and is headquartered in Copenhagen, Denmark. | Health Technology |
The European Commission | Government |
Teknologisk Institut
Teknologisk Institut Miscellaneous Commercial ServicesCommercial Services Teknologisk Institut develops, applies, and disseminates research- and technology-based knowledge for the Danish business. It is an independent, non-profit institution that provides training courses and conferences including information technology courses; energy and construction; project; personal development; leadership; productivity, measuring technology, and logistics; quality; food and environment; communication; sales and marketing; and human resource, law, and economics. In addition, it also carries out consultancy and standardization activities. The firm provides services in business areas such as building and construction; business and industrial development; chemistry and biotechnology; energy and climate; environment, working environment, and health; food and packaging; industrial measurements and control; industrial production and development; meat industry solutions; productivity and management; surfaces and microtechnology; and transport and logistics. The company was founded by Gunnar Gregersen in 1906 and is headquartered in Taastrup, Denmark. | Commercial Services |
SEED Capital Management I/S
SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark. | Finance |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Health Technology |
BKG Pharma ApS
BKG Pharma ApS Pharmaceuticals: MajorHealth Technology BKG Pharma ApS develops and commercializes novel antibiotics against multidrug-resistant bacteria. It conducts research and development on treatment for multi-resistant infections such as resistance to chemotherapy. The company was founded by Birgit K. Giwercman in 2004 and is headquartered in Copenhagen, Denmark. | Health Technology |
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Conrig Pharma ApS
Conrig Pharma ApS Pharmaceuticals: MajorHealth Technology Conrig Pharma ApS provides drug for oral treatment of atopical disease. Its new drug (CRG-010) is use for topical treatment of itch/pruritus associated with atopical dermatitis. The company was founded by John Bondo Hansen and Mikael Sondergaard Thomsen on December 20, 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Diet4life ApS
Diet4life ApS BiotechnologyHealth Technology Diet4life ApS produces dietary supplements to reduce fat accumulation and induce weight loss in the human body. It evaluate the long-term effects of regular protein intake in conjunction with certain food products and the suitability for being a dietary supplement. The company was founded on March 4, 2013 and is headquartered in Aarhus, Denmark. | Health Technology |
Medical Prognosis Institute A/S
Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark. | Health Technology |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
Adject ApS
Adject ApS Medical SpecialtiesHealth Technology Adject ApS is a holding company that specializes in the design, development, production, and sales and marketing of auto disable syringes. It engages in the preparation of pharmaceutical compositions. It develops syringe that self-destructs after use. The company was founded by Michael Hans Andranik Hetting on December 22, 2009 and is headquartered in Charlottenlund, Denmark. | Health Technology |
Besst-Test ApS | |
Biotech Af 14 Maj 2014 ApS | |
Cn Af 2 Maj 2012 A/S
Cn Af 2 Maj 2012 A/S Food: Major DiversifiedConsumer Non-Durables Cn Af 2 Maj 2012 A/S provides clean label food extracts. It product offerings encompass beef and veal, lamb, pork, chicken, duck, game, crab, mussel and fish extracts. The company was founded in 2008 and is headquartered in Logstor, Denmark. | Consumer Non-Durables |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Valderm ApS
Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Health Technology |
Victorious Medical Systems ApS |
- Borsa valori
- Insiders
- Frank Knudsen
- Esperienza